Data / Form D filings / Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.: Form D filings
Relmada Therapeutics, Inc., a biotechnology company in New York, NY, filed 4 Form D notices with the SEC between 2012 and 2014. The latest, on May 22, 2014, reports $15.1 million sold of a $15.1 million offering to 225 investors.
Find out what Relmada Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 546 FIFTH AVENUE, 14TH FLOOR, New York, NY, 10036
- Phone
- (212) 702-7163
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1554535
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 22, 2014 | New notice | $15,051,110 | $15,051,110 | $0 | 225 | May 12, 2014 | sec.gov |
| Jun 7, 2013 | New notice | $750,000 | $180,000 | $570,000 | 6 | Dec 6, 2012 | sec.gov |
| Jun 6, 2013 | Amendment | $8,000,000 | $4,955,500 | $3,044,500 | 98 | Jul 10, 2012 | sec.gov |
| Jul 23, 2012 | New notice | $6,000,000 | $3,008,000 | $2,992,000 | 61 | Jul 10, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Eliseo O. Salinas | Executive Officer | |
| Douglas O. Beck | Executive Officer | |
| Sandesh O. Seth | Director | |
| Shreeram O. Agharkar | Director | |
| Nabil M. Yazgi | Director | |
| Sergio Traversa | Executive Officer, Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of May 19, 2014 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Relmada Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.